Hainan Huluwa Pharmaceutical Group Co Ltd (605199) — Cash Flow-to-Debt Ratio
Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of CN¥44.34 Million could theoretically repay 0% of its total liabilities (CN¥2.06 Billion) in one year. See Hainan Huluwa Pharmaceutical Group Co Lt (605199) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hainan Huluwa Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Hainan Huluwa Pharmaceutical Group Co Ltd across 10 annual periods. For the full cash flow conversion analysis, see 605199 operating cash flow.
Annual Cash Flow-to-Debt Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)
Year-by-year debt coverage analysis for Hainan Huluwa Pharmaceutical Group Co Ltd. Check Hainan Huluwa Pharmaceutical Group Co Lt cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | CN¥136.85 Million | CN¥2.14 Billion | ▲ +195.0% |
| 2024 | -0.07x | CN¥-149.12 Million | CN¥2.22 Billion | ▼ -551.7% |
| 2023 | 0.01x | CN¥28.25 Million | CN¥1.90 Billion | ▼ -91.9% |
| 2022 | 0.18x | CN¥238.71 Million | CN¥1.30 Billion | ▲ +49.2% |
| 2021 | 0.12x | CN¥102.48 Million | CN¥830.41 Million | ▲ +2161.5% |
| 2020 | 0.01x | CN¥3.30 Million | CN¥604.68 Million | ▼ -98.3% |
| 2019 | 0.33x | CN¥144.51 Million | CN¥442.67 Million | ▲ +400.4% |
| 2018 | 0.07x | CN¥31.80 Million | CN¥487.37 Million | ▼ -66.9% |
| 2017 | 0.20x | CN¥89.96 Million | CN¥455.83 Million | ▲ +23.7% |
| 2016 | 0.16x | CN¥64.96 Million | CN¥407.26 Million | — |